Last reviewed · How we verify

NCT04183218

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

Completed Last updated 23 August 2024
What this trial tests

trial testing Biospecimen Collection in Clinical Stage 0 Esophageal Adenocarcinoma AJCC V8 in 24 participants. Completed in 2 May 2024.

Timeline
23 September 2019
Primary endpoint
6 January 2024
2 May 2024

Quick facts

Lead sponsorMayo Clinic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment24
Start date23 September 2019
Primary completion6 January 2024
Estimated completion2 May 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Clinical Stage 0 Esophageal Adenocarcinoma AJCC V8 or Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC V8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies cardiac changes after radiation or chemo-radiation for the treatment of lung or esophageal cancer that has not spread to other places in the body (non-metastatic) or has not come back (non-recurrent). Continuous cardiac monitoring with an implanted device may help to identify cardiac changes that would remain unnoticed, and facilitate the treatment of these early cardiac changes as part of standard care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04183218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing